{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:48:42Z","timestamp":1790513322265,"version":"4.1.0"},"reference-count":10,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Adverse effects have limited the clinical use of telithromycin. Preferential inhibition of the nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction (\u03b13\u03b22 and NMJ), the ciliary ganglion of the eye (\u03b13\u03b24 and \u03b17), and the vagus nerve innervating the liver (\u03b17) could account for the exacerbation of myasthenia gravis, the visual disturbance, and the liver failure seen with telithromycin use. The studies presented here enable the prediction of expected side effects of macrolides in development, such as solithromycin (CEM-101).<\/jats:p>","DOI":"10.1128\/aac.00840-10","type":"journal-article","created":{"date-parts":[[2010,9,21]],"date-time":"2010-09-21T00:51:28Z","timestamp":1285030288000},"page":"5399-5402","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":69,"title":["Molecular Characterization of Off-Target Activities of Telithromycin: a Potential Role for Nicotinic Acetylcholine Receptors"],"prefix":"10.1128","volume":"54","author":[{"given":"Daniel","family":"Bertrand","sequence":"first","affiliation":[{"name":"HiQScreen Sa\u0300rl, 15 rue de l'Athe\u0301ne\u0301e, 1206 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Bertrand","sequence":"additional","affiliation":[{"name":"HiQScreen Sa\u0300rl, 15 rue de l'Athe\u0301ne\u0301e, 1206 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Neveu","sequence":"additional","affiliation":[{"name":"HiQScreen Sa\u0300rl, 15 rue de l'Athe\u0301ne\u0301e, 1206 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhavathi","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Cempra Pharmaceuticals Inc., Chapel Hill, North Carolina 27514"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00015.2008"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.47.120505.105214"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2007.11.028"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.3.825"},{"key":"e_1_3_2_6_2","first-page":"861","volume":"86","year":"2008","unstructured":"Jarvis, L. M. 2008. The Ketek effect. Chem. Eng. News86:861-862.","journal-title":"Chem. Eng. News"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2010.02.005"},{"key":"e_1_3_2_8_2","first-page":"1579","volume":"37","year":"2003","unstructured":"Nieman, R. B., K. Sharma, H. Edelberg, and S. E. Caffe. 2003. Telithromycin and myasthenia gravis. Clin. Infect. Dis.37:1579.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544090-00003"},{"key":"e_1_3_2_10_2","first-page":"427","year":"2005","unstructured":"Sivapalasingam, S., and N. H. Steigbigel. 2005. Increase in pneumococcus macrolide resistance, United States, p. 427-448. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Elsevier, Philadelphia, PA.","journal-title":"Increase in pneumococcus macrolide resistance, United States,"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(95)11824-G"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00840-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00840-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:24:12Z","timestamp":1645457052000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00840-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1128\/AAC.00840-10"],"URL":"https:\/\/doi.org\/10.1128\/aac.00840-10","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.7869956.8218054","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"2010-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-09-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-12-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}